Relationship between the antithrombotic effect of YM-75466, a novel factor Xa inhibitor, and coagulation parameters in rats

European Journal of Pharmacology
K SatoY Matsumoto

Abstract

The relationship between the antithrombotic effects of intravenous infusions of YM-75466 [N-[4-[(1-acetimidoyl-4-piperidyl)oxy]phenyl]-N-[(7-amidino-2-naph thyl)methyl] sulfamoyl]acetic acid monomethanesulfonate), a novel factor Xa (FXa) inhibitor, and various coagulation parameters (prothrombin time, activated partial thromboplastin time, thrombin-antithrombin III complex (TAT), anti-FXa activity and anti-thrombin activity) in rats was studied and compared with results for heparin. In the arterio-venous shunt model, both agents exerted antithrombotic effects in a dose-dependent manner. Coagulation parameters were studied simultaneously with antithrombotic effects. YM-75466 did not prolong coagulation time even at the dose which exerted significant antithrombotic effects, while it decreased TAT level in plasma in a dose-dependent manner. YM-75466 exerted anti-FXa activity but not anti-thrombin activity. In contrast, heparin prolonged activated partial thromboplastin time in a dose-dependent manner and decreased TAT level in plasma with increasing inhibition of thrombus formation. Heparin exerted both anti-FXa and anti-thrombin activity in a dose-dependent manner. These results suggest that TAT is a suitable parameter for monito...Continue Reading

References

Oct 1, 1991·American Journal of Hematology·K DeguchiK Tanaka
Jul 1, 1995·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·C RavanatC Legrand
Dec 1, 1995·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·I MacGregorO Drummond

❮ Previous
Next ❯

Citations

Sep 30, 2000·Thrombosis Research·V ChuC T Dunwiddie
Sep 20, 2001·Thrombosis Research·V ChuR J Leadley
Mar 13, 1999·Thrombosis Research·J Hauptmann, J Stürzebecher
Jan 11, 2001·Journal of Pharmacological and Toxicological Methods·R J LeadleyA Gagnon
Jun 17, 2011·Cardiovascular Research·Martina DelbeckGeorges von Degenfeld
Oct 19, 2001·Chemical & Pharmaceutical Bulletin·H NishidaH Mochizuki
Sep 12, 2000·Current Cardiology Reports·F A Spencer, R C Becker
Nov 2, 2011·European Journal of Pharmacology·Yoshiyuki IwatsukiSeiji Kaku
Mar 8, 2005·Journal of Thrombosis and Haemostasis : JTH·E PerzbornA Straub
May 15, 2012·Expert Opinion on Drug Metabolism & Toxicology·Lakshmi GopalakrishnanC Michael Gibson
Mar 12, 2002·Bioorganic & Medicinal Chemistry·Fukushi HirayamaIsao Yanagisawa
Nov 20, 2002·The Journal of Pharmacology and Experimental Therapeutics·Pancras C WongRobert M Knabb
Dec 23, 2004·Journal of Thrombosis and Haemostasis : JTH·K KarnickiJ H Chesebro
Jan 27, 2005·Bioorganic & Medicinal Chemistry·Hiroyuki KoshioShin-ichi Tsukamoto

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.